# Incarceration and Public Health

## Introduction

The United States incarcerates approximately **1.9 million people** in federal and state prisons, local jails, and other detention facilities, the highest incarceration rate in the world. **Mass incarceration** disproportionately affects Black, Hispanic, and low-income communities, amplifying existing health inequities. Incarcerated populations have a constitutional right to healthcare under the **Eighth Amendment** (Estelle v. Gamble, 1976), making correctional facilities the only setting in the U.S. with a legal guarantee of healthcare. The health effects of incarceration extend far beyond the individual, affecting families, communities, and intergenerational health outcomes.

## Epidemiology of Health in Correctional Settings

### Infectious Diseases

**HIV prevalence** in prisons is approximately 3-5 times higher than in the general population; jails serve as critical points for testing and linkage to care. **Hepatitis C virus (HCV)** prevalence is estimated at 17-25% among incarcerated individuals, compared to approximately 1% in the general population. **Tuberculosis**: Incarcerated populations have 6-10 times higher rates of latent TB infection; congregate settings with poor ventilation facilitate transmission. **STIs**: High rates of syphilis, gonorrhea, and chlamydia, particularly among incarcerated women. **COVID-19**: Prisons and jails experienced devastating outbreaks with infection rates 5-6 times higher than surrounding communities.

| Health Condition | Prevalence (Incarcerated) | Comparison to General Population |
|---|---|---|
| HIV | 1.3-1.5% | 3-5x higher |
| Hepatitis C | 17-25% | ~17-25x higher |
| Latent TB infection | 15-25% | 6-10x higher |
| Serious mental illness | 15-20% | 3-4x higher |
| Substance use disorders | ~65% | 5-6x higher |
| Hypertension/Diabetes/Asthma | 40-50% higher than age-matched | Significant excess burden |

### Chronic Diseases

**Hypertension, diabetes, and asthma** are highly prevalent; many individuals enter correctional facilities with undiagnosed or poorly managed chronic conditions. Chronic disease prevalence among incarcerated individuals is approximately **40-50% higher** than age-matched community populations. Correctional settings represent an opportunity for **disease identification and management** for populations who may have limited access to healthcare in the community.

### Mental Health and Substance Use

Approximately **37% of incarcerated individuals** in state prisons have been told by a mental health professional they have a mental disorder. **Serious mental illness** (schizophrenia, bipolar disorder, major depression) affects approximately 15-20% of incarcerated individuals. **Substance use disorders** affect an estimated 65% of the incarcerated population; only approximately 11% receive treatment. Jails have become de facto **psychiatric facilities**, housing more individuals with mental illness than all psychiatric hospitals combined.

<image>Comparative infographic showing disease prevalence rates between incarcerated and general populations for HIV, hepatitis C, tuberculosis, serious mental illness, substance use disorders, hypertension, and diabetes, with bar charts demonstrating the magnitude of disparity for each condition</image>

## Structural Drivers of Health in Carceral Settings

### Conditions of Confinement

**Overcrowding** increases infectious disease transmission, psychological distress, and violence. **Solitary confinement** (restrictive housing) is associated with severe psychological harm, including hallucinations, self-harm, and suicide; the UN considers prolonged solitary confinement (>15 days) a form of torture. Inadequate **nutrition, sanitation, and temperature control** contribute to poor health. Limited access to **exercise and outdoor recreation** exacerbates chronic disease.

### Healthcare Delivery Challenges

**Privatization** of correctional healthcare has been associated with cost-cutting that compromises quality. **Formulary restrictions** may limit access to evidence-based medications, including medications for opioid use disorder (MOUD) **Delayed care**: Bureaucratic barriers, co-pays (even nominal), and inadequate staffing lead to delays in accessing healthcare. **Continuity of care** is disrupted by transfers between facilities, lack of integrated medical records, and poor communication with community providers.

## Preventive Services in Correctional Settings

### Screening Opportunities

**HIV testing**: CDC recommends opt-out HIV testing in correctional settings. **HCV screening**: Universal screening at intake is recommended; direct-acting antivirals (DAAs) are cost-effective in this population but access remains limited. **TB screening**: Intake screening with symptom questionnaire and chest radiograph or IGRA/TST. **Cancer screening**: Cervical cancer screening for women; age-appropriate colorectal and breast cancer screening. **Mental health and suicide risk assessment**: Standardized screening at intake and throughout incarceration.

### Harm Reduction

**Medications for opioid use disorder (MOUD)**: Methadone, buprenorphine, and naltrexone reduce opioid overdose mortality, criminal recidivism, and HIV transmission; the majority of correctional facilities still do not offer all three FDA-approved MOUD. **Naloxone distribution** at release is a critical overdose prevention intervention. **Syringe services programs**: Very few correctional facilities have implemented these despite evidence of effectiveness. **Condom distribution**: Recommended by CDC and WHO but available in fewer than 1% of U.S. correctional facilities.

<image>Flowchart showing the ideal public health approach to correctional health, from intake (comprehensive screening for infectious diseases, chronic conditions, mental health, and substance use) through incarceration (evidence-based treatment, chronic disease management, preventive services, health education) to reentry (transition planning, linkage to community providers, insurance enrollment, naloxone distribution, MOUD continuation)</image>

## Reentry and Community Health

### The Critical Post-Release Period

The **first two weeks** after release from incarceration carry the highest risk of death, primarily from drug overdose (12.7 times the risk of the general population) Disruption of **medication continuity** for chronic conditions (HIV, diabetes, hypertension, mental illness) is common and dangerous. **Medicaid enrollment**: Most states now suspend rather than terminate Medicaid during incarceration, but re-enrollment delays create coverage gaps. The **Medicaid Reentry Act** provisions allow Medicaid coverage to begin 30 days before release.

### Reentry Health Planning

**Transition planning** should begin at intake, not at discharge; should include appointment scheduling, medication supply, insurance enrollment, and housing referrals. **Warm handoffs** to community providers improve linkage to care, particularly for HIV treatment and MOUD. **Community health workers** and peer navigators with lived experience of incarceration are effective in supporting reentry health. **Collateral consequences** of conviction (employment discrimination, housing restrictions, food assistance bans) create structural barriers to health.

## Impact on Families and Communities

An estimated **2.7 million children** in the U.S. have a parent in prison or jail. **Parental incarceration** is an adverse childhood experience (ACE) associated with behavioral problems, educational difficulties, and intergenerational criminal justice involvement. Mass incarceration concentrates in specific neighborhoods, creating **community-level trauma** and depleting social capital. The economic impact on families includes lost income, legal costs, phone/visitation expenses, and long-term earning potential reduction.

<image>Ecological model showing the ripple effects of incarceration on health at individual level (disease exposure, trauma, healthcare disruption), family level (parental separation, economic hardship, childhood ACEs), community level (social capital depletion, concentrated disadvantage, stigma), and societal level (racial disparities, healthcare costs, workforce impact), with concentric circles expanding outward from the incarcerated individual</image>

## Key Clinical Pearls

The post-release period is the most dangerous time for formerly incarcerated individuals; overdose deaths are concentrated in the first two weeks, making naloxone distribution and MOUD continuation at release potentially lifesaving. Correctional settings represent a paradoxical public health opportunity: the constitutional guarantee of healthcare means that screening, vaccination, and chronic disease management can reach populations otherwise disconnected from care. Solitary confinement causes measurable psychological harm and should be opposed as a public health issue; medical and mental health professionals should not participate in clearance for placement in solitary. Addressing the health effects of mass incarceration requires upstream interventions including decarceration, diversion to treatment, and investment in communities most affected by the carceral system.

## References

1. Binswanger IA, Stern MF, Deyo RA, et al. Release from prison -- a high risk of death for former inmates. *N Engl J Med*. 2007;356(2):157-165.
2. Wildeman C, Wang EA. Mass incarceration, public health, and widening inequality in the USA. *Lancet*. 2017;389(10077):1464-1474.
3. Rich JD, Beckwith CG, Macmadu A, et al. Clinical care of incarcerated people with HIV, viral hepatitis, or tuberculosis. *Lancet*. 2016;388(10049):1103-1114.
4. National Commission on Correctional Health Care. *Standards for Health Services in Prisons*. Chicago: NCCHC; 2018.